Oracea Articles
HalcyGen to buy fellow Australian drugmaker Mayne Pharma for $15 million
25 September 2009
Mylan group sued over for first-to-file ANDAs
27 March 2009
Warner Chilcott gets FDA response to citizens petition
23 March 2009
Patent suit filed in USA over Doryx generic
12 January 2009
APP Puerto Rico heparin facility cleared by FDA
1 September 2008
EMEA delays Oracea ruling until 2008
6 August 2007
Mylan gains final FDA OK for doxycycline 15mg ANDA
18 June 2007
CollaGenex signs Oracea deal with MediGene
22 December 2006
MediGene AG builds dermatolgy sales force
22 December 2006
Headlines 25 years ago this week....
11 December 2006
Oracea approved by FDA for rosacea
5 June 2006
New Warner Chilcott posts 1st-qtr loss
11 July 2005
IVAX gets approval for doxycycline
23 May 2005
Bradley closes acquisition of Bioglan
16 August 2004
Bradley to buy Bioglan in $183M deal
21 June 2004
Promising new data for CollaGenex' Periostat
23 February 2004
Galen reports 105% leap in 1st-qtr sales
16 February 2004
India's NPPA seeks to recover millions of rupees from 50 local companies
15 September 2003
Stock Commentary - Europe
26 May 2003
Galen's profits grow as sales rocket 57%
19 May 2003
Galen EPS leaps 35%, beating forecasts
17 February 2003
CollaGenex drug starts pivotal trial in rosacea
19 August 2002
Periostat cleared for marketing in Israel
13 May 2002
CollaGenex revenues up 53% in first quarter
29 April 2002
CollaGenex revenues rise 45%
18 February 2002
Pfizer updates Vibramycin labeling
22 November 2001
US bill to ease urgent generic Rx production
12 November 2001
IVAX to make doxycycline as anthrax treatment in USA
6 November 2001
IVAX profits leap, but Onxol disappoints
29 October 2001
Indian firms prepare to make anti-anthrax drugs
24 October 2001
Pharma DTC web sites failing to address consumer needs, says study
14 September 2001
Court frees 7 drugs from India's DPCO
3 September 2001
Atridox cleared in Switzerland
5 July 2001
Atridox cleared in three European countries
10 May 2001
Galen 2nd-qtr profits and revenues soar
2 May 2001
Bioglan sees net leap 85%, sales up 66%
20 April 2001
OraPharma's Arestin approved in USA
19 February 2001
New Periostat formulation cleared in USA
8 February 2001
Ranbaxy antibiotics cleared in USA
7 December 2000
Atrix periodontal product approved by FDA
19 September 2000
Bayer's Cipro backed for anthrax exposure
2 August 2000
France orders halt of doxycycline sales
28 March 2000
UK approves PerioStat
2 March 2000
Atrix Labs gets European backing for Atridox
11 January 2000
Atrix strategy change?
16 September 1999
Atrix poised for long-term growth in drug delivery
16 July 1999
First Euro approval for Atrix' Atridox
29 April 1999
Atrix' Atridox Now Available In USA
26 November 1998
CollaGenex files for Periostat in UK
5 November 1998
First Oral Periodontitis Treatment In USA
8 October 1998
US Launch Of Atridox For Periodontitis
18 September 1998
Milestone Payment For Atrix On Atridox/Atrigel Approval
18 September 1998
Pharmaceutical Companies Face Up To The Future
15 June 1998
Loss Per Share Narrows At Warner Chilcott
8 May 1998
Atrix' Dental Product Approvable In USA
15 April 1998
FDA Regulatory News In Brief
4 February 1998
Atrix Submits Atridox Dossier To MCA
16 October 1997
First Approval For Glaxo Wellcome's Grepafloxacin
4 August 1997
Periostat Filed In First European Market
24 July 1997
Atridox Filing Accepted In USA
12 June 1997
Atrix Submits NDA For Atridox
21 April 1997
FDA Accepts Filing Of Collagenex Pharmaceuticals' Periostat
2 December 1996
Good Clinical Trial Results For Atrix' Periodontal Product
9 September 1996
Three JVs Set Up In Kaifeng, China
22 July 1996
Bentley Pharma Deal With Juventus Spain
19 February 1996
World News Reports In Brief
25 September 1995
ZITHROMAX AND CHLAMYDIA
5 October 1992
Showing 1-74 of 74 articles
- 1
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
